Encouraging news for treatment targeting retinitis pigmentosa

While most people probably wouldn’t put 2020 in their list of favorite years, it’s certainly turning out to be a good one for jCyte. Earlier this year jCyte entered into a partnership with global ophthalmology company Santen Pharmaceuticals worth up to $252 million. Then earlier this week they announced some encouraging results from their Phase … Continue reading Encouraging news for treatment targeting retinitis pigmentosa

Study shows sleep deprivation impairs stem cells in the cornea 

We spend around one third of our life sleeping—or at least we should. Not getting enough sleep can have serious consequences on many aspects of our health and has been linked to high blood pressure, heart disease and stroke.  A study by the American Sleep Apnea Association found that some 70 percent of Americans report getting … Continue reading Study shows sleep deprivation impairs stem cells in the cornea 

Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers

While there have been some encouraging advances in treating cancer in recent decades, there are still many cancers that either resist treatment or recur after treatment. Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing in a therapy targeting some of these hard-to-treat tumors. BioEclipse Therapeutics Inc. was awarded nearly … Continue reading Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers

Identifying the visually impaired patients most likely to benefit from jCyte’s stem cell therapy

We have written about jCyte many times on The Stem Cellar. For one reason, they are showing really encouraging results in their treatment for retinitis pigmentosa (RP). And now they have taken an even deeper dive into those results and identified which patients may be most likely to benefit from the therapy. RP is a … Continue reading Identifying the visually impaired patients most likely to benefit from jCyte’s stem cell therapy

Inspiring new documentary about stem cell research

2020 has been, to say the very least, a difficult and challenging year for all of us. But while the focus of the world has, understandably, been on the coronavirus there was also some really promising advances in stem cell research. Those advances are captured in a great new documentary called Ending Disease. The documentary … Continue reading Inspiring new documentary about stem cell research

Rare Disease: An Uphill Battle for Diagnosis and Treatment

THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST When Dalia was 5 years old, she was finally diagnosed with MERRF syndrome– an extremely rare form of mitochondrial disease. By then, her parents had been searching for an answer for three frustrating years. And like most parents of a child suffering from an undiagnosed medical … Continue reading Rare Disease: An Uphill Battle for Diagnosis and Treatment

jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa

Stepping out of the darkness into light. That’s how patients are describing their experience after participating in a CIRM-funded clinical trial targeting a rare form of vision loss called retinitis pigmentosa (RP). jCyte, the company conducting the trial, announced 12 month results for its candidate stem cell-based treatment for RP. RP is a genetic disorder … Continue reading jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa